Verition Fund Management’s Translational Development Acquisition Corp Warrants TDACW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$253K Sell
191,700
-256,295
-57% -$257K ﹤0.01% 1789
2026
Q1
$71.7K Hold
447,995
﹤0.01% 2080
2025
Q4
$139K Sell
447,995
-3,142
-0.7% -$1.03K ﹤0.01% 3266
2025
Q3
$131K Sell
451,137
-6,101
-1% -$1.65K ﹤0.01% 3560
2025
Q2
$133K Buy
457,238
+286,374
+168% +$59.2K ﹤0.01% 3447
2025
Q1
$26.7K Buy
+170,864
New +$30.1K ﹤0.01% 3230

Other funds holding TDACW

Verition Fund Management's TDACW Position: Q2 2026 in Review

Verition Fund Management reduced its Translational Development Acquisition Corp Warrants (TDACW) stake by 57% in Q2 2026, selling an estimated $257K and leaving 191,700 shares worth $253K. The position accounts for ﹤0.01% of the portfolio, ranked #1789.

Verition Fund Management first reported a position in TDACW in Q1 2025 and has held it in 6 quarters since. 28 funds tracked by Wall St. Rank hold TDACW as of Q2 2026.

  • Verition Fund Management held 191,700 shares of Translational Development Acquisition Corp Warrants worth $253K as of Q2 2026.
  • Verition Fund Management sold 256,295 Translational Development Acquisition Corp Warrants shares in Q2 2026, an estimated $257K.
  • Translational Development Acquisition Corp Warrants made up ﹤0.01% of Verition Fund Management's portfolio in Q2 2026, its #1789 holding.
  • Verition Fund Management first reported a position in Translational Development Acquisition Corp Warrants in Q1 2025 and has held it in 6 quarters since.
  • 28 funds tracked by Wall St. Rank held Translational Development Acquisition Corp Warrants as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.